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Background: Inappropriate fluid therapy during surgery is associated with significant morbidity and mortality. Few
studies have examined the effects of particular types of fluids (crystalloid or colloid solutions) in surgical patients,
especially with the goal of hemodynamic optimization. Isotonic saline is the most commonly used fluid worldwide
but may be associated with potential nephrotoxicity. Hydroxyethyl starch (HES) solutions are widely used in surgical
patients as a component of goal-directed fluid optimization strategies, but several large multicenter studies have
suggested increased rates of acute kidney injury and adverse events with the use of HES in ICU patients. Despite
what may be inferred from physiological studies, the benefit and harm of 0.9 % saline and HES during hemodynamic
therapy have not been clearly established in surgical patients.
Methods/Design: The FLASH trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded,
two-arm trial, randomizing 826 patients with moderate-to-high risk of postoperative complications to receive 6 % HES
130/0.4 or 0.9 % saline during individualized goal-directed fluid optimization. The primary outcome measure is a
composite of death or major postoperative complications within 14 days following surgery.
The sample size will allow the detection of a 10 % absolute between-group difference in the primary outcome measure
with a type 1 error rate of 5 % and power of 95 %, assuming a 5 % mortality rate and 20 % morbidity (thus 25 % for the
composite endpoint).
Discussion: The FLASH trial may provide important data on the efficacy and safety of commonly used fluid solutions and
could have a significant impact on future treatment of surgical patients.
Trial registration: ClinicalTrials.gov Identifier: NCT02502773. Registered 16 June 2015.
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Approximately 230 million patients undergo surgery
worldwide each year, and recent data from the literature
indicate that postoperative mortality ranges from 4 % after
elective noncardiac surgery to 20 % in those undergoing
emergency abdominal surgery [1, 2] and postoperative
complications in 20 to 40 % of those patients considered
to be at moderate-to-high risk of postoperative complica-
tions [3, 4].
Intravenous fluid therapy is one of the most common
interventions in acute medicine [5] and a central aspect of
perioperative management insofar as inappropriate fluid
management in surgical patients is associated with
increased postoperative morbidity, including postoperative
organ dysfunctions [6–8], and mortality [9, 10]. Isotonic
(0.9 %) saline is the most commonly used fluid worldwide
[11]. Few studies, however, have examined the effects of
particular types of fluids (crystalloid or colloid solutions)
in surgical patients, the clinical practice in this specific
area being mainly determined by clinician preference and
local tradition [5, 12]; furthermore, much of the available
data has been extrapolated from studies in critically ill
patients. There is, however, increasing evidence that the
type and dose of fluids administered independently affect
patient outcomes [13].
Two large-scale pragmatic multicenter trials have re-
cently been performed to compare crystalloids and different
new-generation and low-molecular-weight preparations of
hydroxyethyl starch (HES) in critically ill patients [14, 15].
The 6S study demonstrated a significant increase in 90-day
mortality in patients with severe sepsis or septic shock
treated with 6 % HES 130/0.4 rather than a balanced crys-
talloid [14]. In the CHEST study, no significant difference
was found in the 90-day mortality, but the use of 6 % HES
130/0.42 was associated with an increased risk of renal
replacement therapy compared with the use of 0.9 % saline
[15]. The two studies showed no significant difference in
short-term hemodynamic resuscitation endpoints. These
data have led the Pharmacovigilance Risk Assessment
Committee (PRAC) of the European Medicines Agency to
suspend the authorization to use HES in cases of sepsis,
burn injury or critically ill patients but have allowed the
continued use of HES in surgical patients. Evidence is also
emerging to suggest that administration of a large volume
of 0.9 % saline may contribute to the development of hyper-
chloremic metabolic acidosis and AKI [16, 17]. The use of
balanced rather than non-balanced crystalloid solutions has
recently been proposed as a pragmatic alternative to 0.9 %
saline, but only limited evidence is currently available
concerning comparable efficacy and safety of use [5, 13]
without demonstration of a clinical benefit in surgical
patients [18, 19].
Several meta-analyses, including studies conducted
on heterogeneous patient groups with a low risk ofcomplications, have been published on colloid use in
surgical patients and showed no difference in terms of
mortality and postoperative acute kidney injury (AKI)
between crystalloids and low molecular weight HES
[20–22]. A growing body of evidence suggests that the
timing of fluid administration is a central aspect of
fluid therapy and that, in surgical patients, hemodynamic
goal-directed therapy (GDT) to increase blood flow can
reduce postoperative morbidity [4, 6–8] and mortality in
the higher-risk groups of patients [9, 10, 23]. A central tenet
of hemodynamic GDT is the individualization of fluid ther-
apy by using explicit goals of care to allow early correction
of fluid deficits and avoid excessive administration by fluid
titration. The importance of individualizing fluid therapy
has particularly been emphasized in a recent statement
from the international Fluid Optimization Group and a
workgroup from the 12th Acute Dialysis Quality Initiative
(ADQI) [24, 25]. To date, however, few studies have exam-
ined the effect of the particular types of fluid used during
hemodynamic therapy, and most studies have used colloid
solutions; therefore, reliable conclusions cannot be drawn.
Despite what may be inferred from physiological studies
[26, 27], available data from HES use in ICU patients
encourage the use of crystalloids as a first-line therapy for
correction of hypovolemia during surgery. Crystalloids and
colloids, however, may not be completely interchangeable.
Greater fluid volumes have been suggested as necessary to
achieve the same hemodynamic targets with crystalloids
than with colloids, with reported crystalloid/colloid ratios
ranging from 1.5 to 4 [28–30]. Administration of excessive
fluid during surgery is associated with an increased risk of
tissue edema, postoperative respiratory complications [31],
renal dysfunction [32], longer hospital stay, and higher
postoperative mortality [33]. An experimental study showed
that, compared to a crystalloid-based goal-directed fluid
therapy, a colloid-based goal-directed fluid therapy using
HES 130/0.4 was associated with a reduction in the total
volume of fluid infused and an improved microcirculatory
blood flow and tissue oxygen pressure in the small intestine
after abdominal surgery [34]. Two other randomized
clinical trials also compared crystalloid with HES in patients
at low risk of complications undergoing abdominal surgery.
One concluded on better hemodynamic stability and re-
duced transfusion of blood products with HES [35],
whereas the other found no difference in postoperative out-
come despite a higher positive fluid balance in patients
treated with crystalloids [36].
Taken together, two hypotheses can be put forward. A
colloid-based goal-directed individualized fluid therapy
using HES may improve outcome compared to 0.9 % saline
or may promote postoperative organ dysfunction and
reduced survival in moderate-to-high risk patients under-
going major surgery. The large number of patients for
whom the question applies each year worldwide, current
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products in surgical patients, and the cost differences
between HES and 0.9 % saline indicate the importance of
evaluating the benefit/risk balance of these products and of
evaluating the influence of the type of solution adminis-




Written consent will be obtained from all participants.
The Institutional Review Board of the University
Hospital of Clermont-Ferrand (France) approved the
trial. By 23 April 2015 the study had been approved
for all centers by a central ethics committee (Comité
de Protection des Personnes Sud-Est VI, Clermont-
Ferrand, France) with the registration number IDRCB
2014-005575-84. The FLASH trial was registered on
16 July 2015 at http://www.clinicaltrials.gov with trial
identification number NCT02502773.
Trial design
The FLASH (fluid loading in abdominal surgery: saline
versus hydroxyethyl starch) trial is an investigator-
initiated, national, multicenter, parallel randomized
controlled two-arm trial with concealed allocation of
moderate-to-high risk patients 1:1 to individualized
goal-directed fluid therapy during abdominal surgery
using 6 % HES 130/0.4 in 0.9 % sodium chloride
solution (Voluven, Fresenius Kabi, Bad Hamburg,
Germany) or 0.9 % sodium chloride (saline).
CONSORT diagram
The Consolidated Standards of Reporting Trials
(CONSORT) diagram of FLASH is presented in Fig. 1.
Selection of participants
Patients will be included in the FLASH trial if they comply
with the indicated inclusion and exclusion criteria.
Inclusion criteria
For inclusion, adult patients must meet all the following
criteria:
1. Elective or emergency abdominal surgery under
general anesthesia
2. An anticipated operating time greater than or equal
to 2 h
3. A moderate-to-high risk of postoperative complications
defined by an AKI risk index ≥ class 3 (see Additional
file 1) [37]
4. From whom written informed consent is obtainable
either from the patient or from a legal representative
(in case of non-elective surgery)Exclusion criteria
Patients will be excluded for any of the following reasons:
1. Age <18 years
2. Patient with acute heart failure
3. Patient with acute coronary insufficiency
4. Patient with severe renal failure (defined by
creatinine clearance <30 ml/min or requiring renal
replacement therapy)
5. Patient with preoperative shock (defined by the need
for vasoactive drugs before surgery)
6. History of allergy with the use of HES 130/0.4
7. Contraindication to the use of HES (as mentioned in
the Summary of Product Characteristics for 6 %
HES 130/0.4, Voluven, Bad Hamburg, Germany:
sepsis, burnt patient, renal insufficiency or dialysis,
cerebral hemorrhage, ICU patient, hypervolemia,
lung edema, dehydration, severe hypernatremia or
severe hyperchloremia, severe hepatic insufficiency,
congestive heart failure, severe coagulopathy, or
organ transplant)
8. Patient’s or relative’s refusal to participate
9. Parturient or breast-feeding women
10.Protected major (guardianship)
Randomization and blinding
Randomization will be conducted over a dedicated,
password-protected, SSL-encrypted website (EOL,
Medsharing, Fontenay-sous-Bois, France) to allow
immediate and concealed allocation. Each patient will
be given a unique patient-number and a randomization
number. The allocation sequence will be generated with
the use of a minimization algorithm stratified according to
center and timing of the surgical procedure (elective or
emergency). The participant allocation will be carried out
by local investigators who will log into the randomization
system using a personal ID code and will enter any
relevant information (including weight to calculate the
maximum daily dose of trial fluid).
Trial fluids (HES and 0.9 % saline) are visually identical
and consist in 500-ml Freeflex fluid bags containing HES
or 0.9 % saline. Trial fluids will be blinded and identified
only by a unique number from the specific trial site. The
initial and any subsequent allocation of trial fluids will be
determined by a web-based randomization system. The
logistics of the trial fluid distribution to each of the 20
participating centers that are anticipated to be recruiting
will be coordinated by the pharmacy of the coordinating
center. The receipt, storage and dispensing of the blinded
trial fluids will be conducted by the pharmacy department
in each individual trial site. Each trial site will have a suffi-
cient number of bags of trial fluid to be allocated to the
included patients. The initial and any subsequent alloca-
tion of trial fluids will be determined by the web-based
Fig. 1 CONSORT flowchart illustrating the randomization and flow of patients in the study
Fig. 2 Trial fluid administration according to the stroke volume-guided
hemodynamic therapy algorithm. Abbreviations: refSVI reference value
of SVI, SVI stroke volume index
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the patient only receives the trial fluid that he/she was
randomized to receive. The information regarding which
codes correspond to what treatment will be maintained in
a secure location at the coordinating center. All staff at
the participating trial sites and the coordinating center will
be blinded to the treatment allocation.
Trial interventions
All included patients will be allocated to one of the
following two study groups:
1. Crystalloid-based GDT. Patients in this group will be
receive individualized goal-directed fluid administration
of 0.9 % saline (Sodium chloride, 500 mL FreeFlex™,
Fresenius Kabi, Bad Hamburg, Germany) to optimize
stroke volume.
2. Colloid-based GDT. Patients in this group will receive
individualized goal-directed fluid administration of
6 % HES 130/0.4 (Voluven™, Fresenius Kabi, Bad
Hamburg, Germany) to optimize stroke volume.
Trial fluid is to be used for volume expansion during
surgery and for a maximum of 24 h after surgery. In
each group, patients will receive 250 ml fluid chal-
lenges of the trial fluids, within a period of 5 min, aim-
ing to maximize stroke volume as suggested by French
and international recommendations for perioperativehemodynamic optimization [24, 38]. In order to ensure
a standardized approach to fluid administration, no
more than 500 ml of trial fluid will be administered for
initial determination of the maximal value of the stroke
volume. Once the maximal value of the stroke volume has
been determined after induction of anesthesia, stroke
volume will be maintained throughout the intervention
period with subsequent boluses of trial fluids as required
(Fig. 2). The clinical decision to administer trial fluids
during the first 24 h after surgery, as with other aspects of
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treating clinician according to routine clinical practice and
the expertise of the staff at each center. In each group, the
maximum dose of trial fluid will be 30 ml/kg/day to
comply with the maximum registered dose of 6 % HES
130/0.4. If the upper limit of the trial fluid is exceeded,
unmasked 0.9 % saline will be used in all patients.
Standard procedures
In all patients, lactated Ringer’s solution will be adminis-
tered at a maximum infusion rate of 4 ml/kg/h to satisfy
the maintenance fluid requirements during surgery.
Decisions about all other aspects of patient care during
the intraoperative and postoperative periods (especially
general anesthesia, postoperative pain management and
physiotherapeutic procedures) will be performed accord-
ing to the expertise of the staff at each center and to
routine clinical practice to minimize interference with
the trial intervention. Nevertheless, trial investigators
will be strongly encouraged to apply standard measures
to avoid extremes of clinical practice, as follows:
1. Mean arterial pressure will be maintained at 60 mmHg
or higher.
2. Oxygenation (pulse oximetry) will be maintained at
94 % or higher.
3. Blood products will be given to maintain hemoglobin
at level greater than 8 g/dl (in patients with no history
of ischemic heart disease or ≥10 g/dl otherwise).
4. Normothermia and normoglycemia will be
maintained throughout the surgical period.
5. Lung-protective ventilation will be used during surgery.
6. Enhanced recovery after surgery (ERAS) guidelines
will be applied.
7. Appropriate prophylactics antibiotics will be used as
recommended.
Outcomes
The primary outcome measure will be a composite of
mortality or major postoperative complications occur-
ring by day 14 after surgery, defined as one or more of
the following:
1. Acute kidney injury (defined by KDIGO stage 1 or
higher)
2. Pulmonary complication (defined by the need for
noninvasive or invasive ventilatory assistance for
postoperative acute respiratory failure)
3. Cardiovascular complication (defined by the
development of acute heart failure)
4. Infectious complication (defined by the development
of sepsis, severe sepsis or septic shock)
5. Surgical complication (defined as the need for
surgical reoperation)In addition, each component of the primary outcome
measure will be analyzed separately.
Secondary outcome measures will be as follows:
1. Postoperative complications evaluated separately
within 14 days:
a. Kidney dysfunction: oliguria (24-h urine
output < 500 ml), KDIGO score
(KDIGO categories [39]:
KDIGO stage 1: increase in serum creatinine × 1.5
to 1.9 OR ≥26.5 μmol/l from baseline OR urine
output <0.5 ml/kg/h for 6 to 12 h
KDIGO stage 2: increase in serum creatinine × 2.0
to 2.9 from baseline OR urine output <0.5 ml/kg/h
for ≥12 h
KDIGO stage 3: increase in serum creatinine × 3.0
from baseline OR ≥353 μmol/l OR initiation of renal
replacement therapy OR urine output <0.3 ml/kg/h
for ≥24 h OR anuria ≥12 h)
b. Cardiovascular complications: cardiac arrhythmia,
acute heart failure, myocardial infarction, or
pulmonary embolism
c. Pulmonary complications: postoperative
hypoxemia, postoperative pneumonia, need for
intubation and invasive mechanical ventilation or
postoperative noninvasive ventilation,
postoperative ARDS, and days alive without
ventilation (ventilator-free days)
d. Postoperative systemic inflammatory response
syndrome (SIRS) score [40]
e. Infectious complications: surgical site infection,
intra-abdominal abscess, postoperative peritonitis,
sepsis, severe sepsis or septic shock
f. Surgical complications: anastomotic leak,
reoperation or endoscopic drainage
g. Sepsis-related organ failure assessment (SOFA,
modified from [41], see Additional file 2) score
(excluded Glasgow Coma Score)
h. Total fluid volume (0.9 % saline and HES 130/0.4)
administered during the surgical period and the
first 24 postoperative hours
i. Volume of blood loss and number of units of
packed red blood cells administered during the
operative period and the first 24 postoperative hours
j. Time to return of bowel function (flatus and
stool)
k. Unexpected ICU admission (or readmission)
within 28 days following surgery
l. Duration of hospital stay: high dependency
unit (HDU), intensive care unit (ICU),
hospital stay
m.All-cause mortality at Day 28 and 3 months
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Trial fluid is to be used only during the surgical period
and for a maximum of 24 h after surgery. Nevertheless,
a participant or a patient’s relative who no longer agrees
to participate in the clinical trial can withdraw the
informed consent at any time without need of further
explanation. Patients who are withdrawn from the trial
fluid-treatment protocol will be followed up and ana-
lyzed as with the remaining patients. In order to conduct
intention-to-treat analyses with as little missing data as
possible, it is in the interest of the trial to collect as
much data from each participant as possible. Therefore,
the investigator may ask the participant and/or relatives
which aspects of the trial he/she wishes to withdraw
from (participation in the remaining follow-up assess-
ments or use of already collected data) and, whenever
possible, and the participant will be asked for permission
to obtain data for the primary outcome measure. If this
person declines, no more data will be collected, and new
patients will be randomized to obtain the full sample
size. All randomized patients will be reported, and all
data available with consent will be used in the analyses.
If appropriate, missing data will be handled in accord-
ance with multiple imputation procedures if missing
data are greater than 5 %.
Safety
All adverse events thought to be related to the trial fluids
will be reported to the trial coordinating center. According
to the French Public Health Code, all suspected unexpected
serious adverse events will be reported to the ANSM. In
addition, this information will be submitted to the data
monitoring and safety committee (DMSC). The DMSC is
independent of the trial investigators and will perform an
ongoing review of safety parameters and overall study
conduct. The DMSC is comprised of two independent
experts in large-scale clinical trials and one independent
statistician.
The DMSC will be responsible for safeguarding the
interests of trial participants, assessing the safety and
efficacy of the interventions during the trial, and for
monitoring the overall conduct of the clinical trial. To
contribute to enhancing the integrity of the trial, the
DMSC may also formulate recommendations relating to
the recruitment/retention of participants, their manage-
ment, improving adherence to protocol-specified regi-
mens and retention of participants, and the procedures
for data management and quality control. The DMSC
will provide recommendations about stopping or
continuing the trial to the Steering Committee (SC) of
the FLASH trial. Stopping rules will be based on the
following:
1. Group-difference in all causes mortality or2. Group-difference in postoperative AKI (requirement
for renal replacement therapy)
The DMSC will be advisory to the SC. The SC will
be responsible for promptly reviewing the DMSC rec-
ommendations, to decide whether to continue or termin-
ate the trial, and to determine whether amendments to
the protocol or changes in trial conduct are required.
Statistics
Analysis will be by intention-to-treat (ITT) on data from
the modified-ITT population (see Additional file 3).
Unadjusted chi-square test or Fisher’s exact test will be
used for the primary outcome analysis. Adjusted analysis
will be conducted with the use of robust random effects
Poisson generalized-linear regression (1) to take into
account adjustment on possible confounding covariates
selected according to clinical relevance and stratification
variables and (2) to consider within and between center
variability. Data will be presented as relative risks and
95 % confidence intervals.
Regardless of the results from the analysis of the
composite outcome, each component of the composite
primary outcome measure will be also analyzed separ-
ately using similar methods as described for the primary
analysis. The Hochberg procedure will be used to adjust
for multiple testing of components of the composite
primary outcome. A chi-square test (or Fisher’s exact
test, as appropriate) will be used for secondary binary
outcomes. Continuous variables will be compared with
the use of the unpaired t-test or Mann–Whitney U test
as appropriate. The Shapiro-Wilk test will be used to assess
homoscedasticity. Adjusted analyses will be performed
using the same adjustments variables. Time-to-event curves
will be calculated with the use of the Kaplan-Meier method.
Longitudinal analysis using mixed models will be used to
take into account within and between subject variability.
Per protocol analyses will be performed on the primary
outcome and the most important secondary outcomes.
Missing data will be handled in accordance with the
multiple imputation method (STATA command mi) if
missing data are greater than 5 % [42].
A total of 2 × 413 patients will be needed to have
95 % power to show an absolute between-group differ-
ence of 10 % in the primary outcome measure at a two-
sided alpha level of 0.05, assuming a 5 % mortality rate
and 20 % morbidity at 14 days after surgery (thus, 25 %
for the composite endpoint). Data from the literature
have shown that postoperative mortality ranges from
4 % in patients undergoing elective noncardiac surgery
to 20 % in those undergoing emergency abdominal
surgery [1, 2, 43], with an average rate of postoperative
complications following major abdominal surgery of 20
to 40 % [3, 4].
Futier et al. Trials  (2015) 16:582 Page 7 of 10Given current concerns related to possible adverse
effects of IV therapy solutions (6 % HES and 0.9 %
saline), an interim safety analysis will be performed after
data for 210 and 420 patients have been obtained using
the Lan and DeMets method (East software, Cytel Inc.,
Cambridge, MA, USA). The DMSC will recommend that
the trial be stopped if it is found that the conduct of the
trial compromises patient safety (a between-group differ-
ence in mortality or postoperative AKI).
All analyses will be conducted with Stata statistical
software, version 12 (StataCorp. 2011. Stata Statistical
Software: Release 12. College Station, TX: StataCorp LP).
A two-sided P value of less than 0.05 will be considered
for statistical significance.
Data registration
Data will be entered into the web-based electronic case re-
port form (eCRF) (EOL, Medsharing, Fontenay-sous-Bois,
France) by trial or clinical personnel under the supervision
of the trial site investigators at each participating center.
Data collection will be monitored by trained research
coordinators.
The following data will be registered:
Pre-randomization and baseline characteristics: Demo-
graphic data (age, height, weight, gender, and body mass
index); co-morbidities (hypertension Y/N, renal dysfunction
Y/N, chronic heart failure Y/N, diabetes mellitus Y/N, mal-
nutrition Y/N, chronic alcoholism Y/N, and active smoking
Y/N); American Society of Anesthesiologists (ASA) physical
status; surgical operation for malignancy Y/N; preoperative
use of nephrotoxic drugs (NSAIDs) Y/N; preoperative use
of angiotensin-converting enzyme inhibitors and/or angio-
tensin II subtype receptor antagonists Y/N; preoperative ad-
ministration (type and volume) of intravenous fluids Y/N;
preoperative administration (and volume) of blood prod-
ucts Y/N; and routine biological data, including baseline
serum creatinine.
At randomization: AKI risk index (class), urgency of
surgery (elective or non-elective surgery) (stratification
variable).
During the surgical procedure, the following data will
be collected:
1. Anesthetic data: type and doses of hypnotics,
opioids and muscle relaxants; duration of
anesthesia; total volume of maintenance fluid;
total volume of trial fluids (aliquots of 250 ml);
use (Y/N) and total volume of 0.9 % saline (if
volume of trial fluid greater than 30 ml/kg); total
number blood products; ventilator settings (tidal
volume, PEEP, FiO2); baseline (and then hourly)
values for bispectral index or entropy; blood
pressures (systolic, diastolic and mean) and stroke
volume index (SVI); type of hemodynamicmonitor (esophageal Doppler Y/N, pulse contour Y/N,
other); total number of episodes of hypovolemia; need
for administration (Y/N) and infusion rate of
vasoactive drugs (ephedrine hydrochloride,
noradrenaline, other); and hourly urine output.
2. Surgical data: type of surgery, duration of surgery,
surgical technique (laparoscopy Y/N, laparotomy Y/N),
total volume of blood losses, and surgical
complications Y/N.
From randomization to postoperative Day 1 (07.59 AM):
total volume of trial fluids (aliquots of 250 ml); use (Y/N)
and total volume of 0.9 % saline (if volume of trial fluid
greater than 30 ml/kg); total number blood products and
blood losses; need for mechanical invasive- or non-invasive
ventilation; hourly values of blood pressures and urine
output; need for administration (Y/N); and infusion rate of
vasoactive drugs.
Daily from postoperative Day 1 (08.00 AM) to Day 7
after surgery (or hospital discharge):
1. Postoperative care pathway (surgical ward Y/N,
HDU Y/N, and ICU Y/N)
2. Epidural analgesia Y/N
3. Daily volume of trial fluid (only on postoperative
Day 1) and maintenance fluids including oral and
parenteral nutrition, urine output and calculated
fluid balance
4. Daily lowest values for heart rate, blood pressure,
peripheral O2 saturation, respiratory rate, temperature
5. Blood glucose level
6. Results of samples of plasma creatinine and creatinine




9. Variables for SOFA scoring not covered above (until
Day 5)
10.Postoperative complications (Y/N, type, and date of
diagnosis)
11.Unexpected ICU admission Y/N
12.Length of stay in HDU, ICU, and surgical ward
13.Date of hospital discharge
14.Death (Y/N and date)
Fourteen days after surgery:
1. Postoperative complications (Y/N, type, and date of
diagnosis)
2. Need for renal replacement therapy on that day Y/N,
and total days of RRT (between first and last
treatment session)
3. Unexpected ICU admission (Y/N, date of admission)
4. Length of stay in HDU, ICU, surgical ward
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6. Survival status (If the patient is deceased, date of death)
If the patient is still present on Day 14, follow up will
continue until hospital discharge.
Twenty-eight days after surgery:
1. Postoperative complications (Y/N, type, and date of
diagnosis) from Day 14 to Day 28 after surgery
2. Survival status
Ninety days after surgery:
1. Survival status (if the patient is deceased, date of death)
Data handling and retention
Data will be handled according to French law. All original
records (including consent forms, reports of suspected
unexpected serious adverse events, and relevant corre-
spondences) will be archived at the trial sites for 15 years.
The clean trial database file will be anonymized and main-
tained for 15 years.
Enrollment and timeline
The patients are expected to be included from 20 French
university and non-university hospitals during a 2-year
period starting in September 2015.
Each participating center has to include two patients
per month (holidays excluded) to finish inclusion in
2 years.
2013–2015: Protocol, approvals from ethics committee,
and trial tool development (eCRF, randomization system)
2015 to 2017: Inclusion of patients
2017: Cleaning and closure of the database.
Early 2018: Data analyses and writing of the manuscript,
and submission for publication.
Publication plan
The trial is registered on http://www.clinicaltrials.gov.
Upon trial completion, the main manuscript will be
submitted to one of the major clinical journals regardless
of the results. All trial sites, including patients, will be
acknowledged, and all investigators at these sites will
appear with their names under ‘the FLASH investigators’
in an Appendix to the final manuscript. The FLASH trial
Steering Committee will grant authorship in adherence
to the Vancouver guidelines and number of patients
enrolled by the individual investigator. If a trial site
investigator is to gain authorship, the site has to include
50 patients or more. If the site includes 80 patients or
more, two authorships will be granted. A writing com-
mittee will be composed of members of the steeringcommittee and investigators to define the order of
authors of any publications.
The listing of authors will be as follows: E Futier (princi-
pal investigator) will be responsible for the writing of the
manuscript and will be the first author, then other mem-
bers of the Steering Committee and trial site investigators
depending on the number of included patients per site
(trial site investigator with the greater number of inclusion
will be second author), B Pereira (biostatistician) will be
second to last author, S Jaber will appear as the last author
and then ‘for the FLASH trial investigators’ will be added.Finances
The FLASH trial is funded by the Agence Nationale de
Sécurité du Médicament (ANSM), the Société Française
d’Anesthesie Réanimation (SFAR) and Clermont-Ferrand
University Hospital.
Fresenius Kabi provides the blinded study treatment
for the conduct of the trial and will manage the ware-
housing and distribution of the study treatment from
the manufacturing plant in France to the coordinating
center (Clermont-Ferrand University Hospital). All blinded
study treatment will be manufactured according to Good
Manufacturing Practice requirements.
Management and logistic of the trial fluid distribution
to each of the 20 participating centers that are antici-
pated to be recruiting will be coordinated using the
web-based randomization system by the pharmacy of
the Clermont-Ferrand University Hospital. The receipt,
storage and dispensing of the blinded trial fluids will be
the responsibility of the pharmacy department in each
individual trial site. This will be performed in ac-
cordance with accredited standards for routine phar-
macy practice.
Funding sources have no influence on trial design,
trial conduct, data handling, data analysis or writing
of the manuscript.Perspectives
Million of patients undergo major abdominal surgery
worldwide each year. Inappropriate (excessive or in-
sufficient) perioperative fluid therapy may be associ-
ated with significant postoperative complications that
adversely affect both short-term and long-term
survival and increase the costs of healthcare. Few
studies, however, have examined the effects of par-
ticular types of fluids (crystalloid or colloid solu-
tions) in surgical patients, and much of the available
data are extrapolated from studies in critically ill
patients. As far as the investigators are aware, no
other large RCTs are assessing the efficacy and safety
of 0.9 % saline or 6 % HES with the goal of
hemodynamic optimization during major surgery.
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Performing the FLASH trial is in line with conclusions
from the 2013 recommendations of the European
Medicines Agency’s Pharmacovigilance Risk Assess-
ment Committee on the lack of robust safety data of
HES in patients undergoing surgical procedures and
the need to perform additional studies with HES solu-
tions in surgical patients, especially in those at high
risk of postoperative complications.
HES solutions are widely used in surgical patients as a
component of hemodynamic therapy for fluid optimization.
Isotonic saline, which is the most widely used fluid world-
wide, is a commonly accepted and effective alternative but
may be associated with potential nephrotoxicity. Whatever
the results of the FLASH trial, this information will provide
urgently needed data on efficacy and safety of commonly
used fluid solutions, which could have a significant impact
on the future treatment of surgical patients.
Trial status
The FLASH trial is not yet recruiting.
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